1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
ImmuneOncia Therapeutics Inc.

ImmuneOncia Therapeutics Inc.

KKRX:424870
2,925.00
KRW
-15.00
(-0.51%)
-365.55EPS
326.47BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.3
0.5
0.72
137.83
1.95
10.8
1.47
- -
Basic EPS, GAAP
-66.88
-1,151.76
-1,957.99
-3,008.51
-3,847.25
-1,209.35
-62.23
156.97
-93.81
-362.25
-365.55
Free Cash Flow per Basic Share
-70.98
-727.11
-1,415.36
-2,868.04
-2,074.71
-41.64
-274.29
-155.23
-244.29
-307.7
-334.69
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
290.04
218.22
97.21
-86.82
-324.82
-757.43
-666.78
-435.03
247.13
354.92
1,099.65
Tangible Book Value per Share
145.86
98.47
-15.46
-183.78
-414.7
-840.17
-742.96
-504.1
184.69
298.68
1,053.18
Basic Weighted Avg Shares
5
5
5
5
5
50
56
56
61
76
80
Sales/Revenue/Turnover
- -
- -
- -
2
3
36
7,733
110
655
111
- -
Operating Margin (%)
- -
- -
- -
-965,315
-505,642.36
-33,094.1
-194.91
-10,726.06
-1,921.22
-25,185.33
- -
Depreciation Expense
- -
1,939
575
773
957
1,026
1,081
1,031
1,051
890
735
Net Income, GAAP
-331
-5,736
-9,751
-14,982
-19,158
-60,490
-3,492
8,864
-5,687
-27,363
-29,306
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-998,818.07
-766,313.41
-168,275.24
-45.15
8,058.2
-868.86
-24,605.12
- -
Working Capital
11,463
7,747
-1,176
26,197
19,348
33,842
25,120
-41,014
13,370
22,247
94,606
LT Debt
- -
- -
- -
55
24
98
24
87
44
15
10
Total Equity
22,797
17,152
7,641
-6,824
-25,530
-59,532
-52,407
-34,192
19,424
28,415
100,281
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-20.54
- -
- -
- -
Return on Common Equity (%)
- -
-28.72
-78.66
- -
- -
- -
- -
- -
- -
-114.4
-39.66

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
55
43
32
LT Borrowings
- -
- -
- -
LT Finance Leases
15
12
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
80
80
91
Market Capitalization
968,218
637,298
326,475

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
26,506
21,057
99,106
Cash, Cash Equivalents & STI
23,438
18,994
93,170
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4,259
3,906
4,500
Payables & Accruals
- -
- -
- -
ST Debt
55
43
32
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-4.81%
46.29%
Free Cash Flow
- -
128.4%
56.95%
Net Income, GAAP
- -
-3.07%
381.15%
Sales/Revenue/Turnover
- -
4,612.98%
-83.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
50
605
655
2025
52
59
- -
- -
111
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-53.87
67.81
-48.86
-93.81
2025
-65.02
-41.8
-130.35
-117.91
-362.25
2026
-70.25
-48
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Heung-Tae Kim
Full Time Employees
22
Sector
Health technology
Industry
Biotechnology
Address
Yongin-si South Korea
IPO Date
May 19, 2025
Website
immuneoncia.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
ImmuneOncia Therapeutics Inc. is a clinical-stage biopharmaceutical company that specializes in the research, development, and commercialization of novel immuno-oncology therapeutics targeting immune checkpoint pathways. Founded in 2016 and headquartered in Yongin-si, Gyeonggi-do, South Korea, the company operates in the biotechnology and pharmaceutical sector as a subsidiary of Yuhan Corporation. ImmuneOncia Therapeutics develops targeted monoclonal and bispecific antibodies designed to harness innate and adaptive immune mechanisms against various solid tumors and hematologic malignancies. The company's core product and development pipeline comprises: IMC-001, a fully human IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1) that mediates antibody-dependent cellular cytotoxicity and is undergoing Phase 2 clinical evaluation for extranodal natural killer/T-cell lymphoma; IMC-002, a fully human IgG4 monoclonal antibody targeting cluster of differentiation 47 (CD47) engineered to disrupt macrophage immune evasion while minimizing red blood cell toxicity and hemagglutination, currently in clinical trials for advanced solid tumors and hematologic indications; IMC-201, a preclinical bispecific antibody candidate engineered to dual-target PD-L1 and CD47 pathways to enhance antitumor selectivity in the tumor microenvironment; and proprietary preclinical antibody discovery programs and macrophage checkpoint modulation platforms. In recent corporate developments, ImmuneOncia Therapeutics transitioned to a consolidated subsidiary of Yuhan Corporation following Yuhan's acquisition of the joint venture equity stake previously held by Sorrento Therapeutics. The company expanded its international commercialization footprint through an exclusive out-licensing and development agreement with 3D Medicines Inc. for IMC-002 in Greater China markets, secured pre-initial public offering funding rounds from institutional venture capital investors, received top-tier technological evaluations for listing on the Korea Exchange (KRX: 424870), and initiated multicenter clinical trials to broaden the therapeutic indications of its lead checkpoint inhibitor candidates across domestic and global markets.